Navigation Links
Study shows no evidence of a mortality benefit to PSA screening
Date:1/6/2012

Men enrolled in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial had no evidence of a mortality benefit compared to a control group of men undergoing usual care, according to a study published online Jan. 6 in the Journal of the National Cancer Institute.

The Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) Trial is a multi-center, two-arm trial, which began enrollment in November 1993 with follow-up through December 2009, and was designed to evaluate the effect of screening on these specific cancers. The enrollees were aged 55-74 and had no previous personal history of these cancers. Men in the intervention arm underwent annual PSA testing for six years and annual digital rectal examination for four years, while those in the control arm received their usual medical care, which for some men included screening. A previous report of PLCO results through ten years was criticized for being too short of a follow-up period.

To determine longer-range outcomes among the men enrolled in PLCO, Gerald L. Andriole, M.D., of Washington University School of Medicine in St. Louis, and colleagues, examined outcomes of the men through 13 years. The researchers found a statistically significant 12% relative increase in the incidence rate of prostate cancer, and a non-statistically significant decrease in the incidence of high-grade prostate cancer in the intervention arm compared to the control arm, but no difference in mortality between the two arms. In addition, there was no apparent differential effect of screening by age category, pre-trial PSA testing, or co-morbidity.

The authors write, "Improvements in prostate cancer treatment are probably at least in part responsible for declining prostate cancer mortality rates. Even if life is only prolonged by therapy, the opportunities for competing causes of death increase, especially among older men."

The authors also point out that of the 4250 prostate cancer case patients diagnosed in the intervention arm, 455 (10.7%) died of causes other than the cancer types studied; in the control arm, 3815 men were diagnosed with prostate cancer of whom 377 (9.9%) died, also of other causes. "Thus, a higher percentage of deaths from other causes rather than a deficit occurred among the prostate cancer patients diagnosed in the intervention arm, an indication of the over-diagnosis associated with PSA detection," the authors write.

The researchers plan to again update the mortality findings from the prostate component of the PLCO after follow-up data through 15 years becomes available.
'/>"/>

Contact: Zachary Rathner
Zachary.Rathner@oup.com
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Study Offers Clues to Why Some Dont Benefit From Asthma Drugs
2. Mice Exposed to Smoke Helped by Blood Pressure Drug: Study
3. Global Study Finds Drug Abuse Highest in Richer Nations
4. Diabetes Care Thwarted by Unstable Health Insurance: Study
5. Moderate red wine drinking may help cut womens breast cancer risk, Cedars-Sinai study shows
6. Mental Decline Can Start at 45, Study Finds
7. Study finds statin costs 400 percent higher in US compared to UK
8. Drug Eases Gout Flare-ups in Some Patients: Study
9. Study Reveals Whos More Prone to Be a Mean Drunk
10. Kaiser Permanente study finds continuous health coverage essential for patients managing diabetes
11. Safety-First Playgrounds Linked to Bored, Inactive Kids: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... MA (PRWEB) , ... April 21, 2017 , ... ... University professor Christopher Salas-Wright finds that youth violence is declining—and at noteworthy rates. ... the relative proportion of young people involved in violence in the United States. ...
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset Protection, ... to communities throughout the greater Pittsburgh metropolitan region, is joining forces with the ... bicycles for differently-abled children. , Variety the Children’s Charity is a national organization ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... announced it’s been named Agency of Record (AOR) for Theravent, Inc. , ... eliminate snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working to expand ...
(Date:4/21/2017)... British Columbia (PRWEB) , ... April 21, 2017 , ... ... at treating people who wish to overcome their mental health struggles. The Alive team ... Director Vic LeBouthillier says: “Our approach in dealing with a mental health struggle is ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... seeking candidates to serve on its Accreditation and Standards Committees to support ... mission is improving image quality and reducing patient radiation dose,” reports Eliot ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... 18, 2017 Cogentix Medical, Inc. (NASDAQ: CGNT), ... Urology, Uro/Gyn and Gynecology markets with innovative and proprietary ... ended March 31, 2017 after the market close on ... will host a conference call and webcast to discuss ... 2, 2017 at 4:30 p.m. Eastern Time (3:30 p.m. ...
(Date:4/18/2017)... DUBLIN , April 18, 2017 Research ... Devices Market 2017-2021" report to their offering. ... The global arthroscopy devices market to grow at ... The report, Global Arthroscopy Devices Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/18/2017)... SAN DIEGO and BLOOMINGTON, ... Pharmaceuticals, Inc. (NASDAQ: IMMY ) ("Imprimis"), ... d/b/a Precision Lens ("Precision Lens"), today announced the ... Under the agreement, Precision Lens will deploy a ... into select geographies in the U.S., primarily focused ...
Breaking Medicine Technology: